The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers.

IF 14.6 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology Pub Date : 2025-09-26 DOI:10.1038/s41585-025-01088-6

Marine Potez,Gabriel Roman Souza,Philippe E Spiess,Shari Pilon-Thomas,Jad Chahoud

{"title":"The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers.","authors":"Marine Potez,Gabriel Roman Souza,Philippe E Spiess,Shari Pilon-Thomas,Jad Chahoud","doi":"10.1038/s41585-025-01088-6","DOIUrl":null,"url":null,"abstract":"Adoptive cell therapy using tumour-infiltrating lymphocytes (TILs) has been a very successful model of enhancing immune-based therapies. Clinical benefits have been shown for patients with advanced melanoma, leading to the first FDA approval for this immune modality in 2024. Although clinical trials conducted decades ago for advanced renal-cell cancer did not show significant clinical benefits, recent advances in the TIL generation process, manipulation techniques, preparative regimens and combination with immune checkpoint inhibitors offer new hope for reexploring optimized TIL therapy for genitourinary cancers. The current landscape of TIL therapy has seen progress in TIL manufacturing, optimization and delivery methodologies that have the potential to improve the safety and efficacy of TIL therapy in the management of advanced genitourinary malignancies. Furthermore, innovative combination approaches and novel strategies could enhance the clinical viability of TIL therapy and warrant evaluation in clinical trials treating patients with genitourinary cancers.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"4 1","pages":""},"PeriodicalIF":14.6000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41585-025-01088-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Adoptive cell therapy using tumour-infiltrating lymphocytes (TILs) has been a very successful model of enhancing immune-based therapies. Clinical benefits have been shown for patients with advanced melanoma, leading to the first FDA approval for this immune modality in 2024. Although clinical trials conducted decades ago for advanced renal-cell cancer did not show significant clinical benefits, recent advances in the TIL generation process, manipulation techniques, preparative regimens and combination with immune checkpoint inhibitors offer new hope for reexploring optimized TIL therapy for genitourinary cancers. The current landscape of TIL therapy has seen progress in TIL manufacturing, optimization and delivery methodologies that have the potential to improve the safety and efficacy of TIL therapy in the management of advanced genitourinary malignancies. Furthermore, innovative combination approaches and novel strategies could enhance the clinical viability of TIL therapy and warrant evaluation in clinical trials treating patients with genitourinary cancers.

查看原文本刊更多论文

发展肿瘤浸润性淋巴细胞治疗晚期泌尿生殖系统癌的机会和障碍。

使用肿瘤浸润淋巴细胞（til）的过继细胞治疗是一种非常成功的增强免疫治疗的模式。已经显示出晚期黑色素瘤患者的临床益处，导致FDA于2024年首次批准这种免疫方式。尽管几十年前对晚期肾细胞癌的临床试验没有显示出显著的临床益处，但最近在TIL生成过程、操作技术、制备方案和与免疫检查点抑制剂联合方面的进展，为重新探索优化TIL治疗泌尿生殖系统癌提供了新的希望。目前，TIL治疗在TIL制造、优化和递送方法方面取得了进展，这有可能提高TIL治疗在晚期泌尿生殖系统恶性肿瘤管理中的安全性和有效性。此外，创新的联合方法和新策略可以提高TIL治疗的临床可行性，并值得在治疗泌尿生殖系统癌患者的临床试验中进行评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Urology 医学-泌尿学与肾脏学

CiteScore

12.50

自引率

2.60%

发文量

123

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.